NASDAQ:SYRE
Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc.'s revenue was $0 in fiscal 2025.Summary generated from Spyre Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−25.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 19 | 2 | 1 | 0 | 0 |
| Operating income | −66 | −85 | −242 | −209 | −210 |
| Net income | −66 | −84 | −339 | −208 | −155 |
| Free cash flow | −54 | −80 | −100 | −157 | n/a |
Recent filings
- 8-KEntry into a material agreement
Oct 7, 2026 - 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 8-KRegulation FD disclosure
Aug 25, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KRegulation FD disclosure
Jun 15, 2026